Tempus AI: HC Wainwright Initiates Buy Coverage with $90 PT
ByAinvest
Tuesday, Sep 2, 2025 7:17 am ET1min read
TEM--
The acquisition of Paige, an AI company specializing in digital pathology, for $81.25 million, is a key factor in HC Wainwright's positive outlook. Paige brings nearly 7 million digitized pathology slide images and associated clinical and molecular data, enhancing Tempus AI's dataset and expanding its technical expertise [1]. This acquisition will help Tempus AI establish a strong footprint in digital pathology and leverage Paige's first FDA-cleared AI tool for pathology.
Additionally, Tempus AI's recent acquisitions of Deep 6 AI and Ambry Genetics have further solidified its position in the healthcare AI market. Deep 6 AI, with its precision research platform, has expanded Tempus AI's reach and improved platforms like Next and TIME, which enhance patient care and connect patients to clinical trials [1]. Ambry Genetics, a genetic testing company, has broadened Tempus AI's healthcare offerings into new areas such as pediatrics, women's health, rare diseases, immunology, and cardiology [1].
Tempus AI's stock has outperformed industry averages and the S&P 500 composite, with year-to-date growth of 121.3% [1]. Despite its strong performance, Tempus AI is currently trading at a forward 12-month Price-to-Sales (P/S) ratio of 9.04X, which is higher than the industry average of 5.90X [1].
HC Wainwright's initiation of buy coverage with a $90 price target reflects the firm's confidence in Tempus AI's growth prospects and technological advancements. As Tempus AI continues to expand its offerings and strengthen its AI capabilities, investors can expect the stock to remain a focal point in the healthcare technology sector.
References:
[1] https://www.nasdaq.com/articles/tempus-key-acquisitions-strengthen-its-ai-healthcare-leadership
[2] https://www.marketscreener.com/news/hc-wainwright-initiates-tempus-ai-at-buy-with-90-price-target-ce7c50d3dc8af023
Tempus AI: HC Wainwright Initiates Buy Coverage with $90 PT
Tempus AI, Inc. (TEM) has received a significant boost in investor confidence following the initiation of buy coverage by HC Wainwright with a $90 price target. The investment research firm has recognized the potential in Tempus AI's strategic acquisitions and technological advancements, positioning the stock favorably for growth.The acquisition of Paige, an AI company specializing in digital pathology, for $81.25 million, is a key factor in HC Wainwright's positive outlook. Paige brings nearly 7 million digitized pathology slide images and associated clinical and molecular data, enhancing Tempus AI's dataset and expanding its technical expertise [1]. This acquisition will help Tempus AI establish a strong footprint in digital pathology and leverage Paige's first FDA-cleared AI tool for pathology.
Additionally, Tempus AI's recent acquisitions of Deep 6 AI and Ambry Genetics have further solidified its position in the healthcare AI market. Deep 6 AI, with its precision research platform, has expanded Tempus AI's reach and improved platforms like Next and TIME, which enhance patient care and connect patients to clinical trials [1]. Ambry Genetics, a genetic testing company, has broadened Tempus AI's healthcare offerings into new areas such as pediatrics, women's health, rare diseases, immunology, and cardiology [1].
Tempus AI's stock has outperformed industry averages and the S&P 500 composite, with year-to-date growth of 121.3% [1]. Despite its strong performance, Tempus AI is currently trading at a forward 12-month Price-to-Sales (P/S) ratio of 9.04X, which is higher than the industry average of 5.90X [1].
HC Wainwright's initiation of buy coverage with a $90 price target reflects the firm's confidence in Tempus AI's growth prospects and technological advancements. As Tempus AI continues to expand its offerings and strengthen its AI capabilities, investors can expect the stock to remain a focal point in the healthcare technology sector.
References:
[1] https://www.nasdaq.com/articles/tempus-key-acquisitions-strengthen-its-ai-healthcare-leadership
[2] https://www.marketscreener.com/news/hc-wainwright-initiates-tempus-ai-at-buy-with-90-price-target-ce7c50d3dc8af023
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet